Business Wire

Rockefeller Capital Management: David Harris Named Chairman of Rockefeller Asset Management; Casey Clark to Succeed Harris as President & CIO

Share

Rockefeller Capital Management today announced the appointment of Casey Clark as President and Chief Investment Officer of Rockefeller Asset Management (RAM). Clark succeeds David Harris, who will become Chairman of RAM while continuing as Senior Portfolio Manager with an exclusive focus on investing for clients.

For the past three years, Clark has served under Harris at RAM as Global Head of ESG Investments and, most recently, as Deputy Chief Investment Officer. He will continue as a member of Rockefeller Capital Management’s management committee. Clark also manages RAM’s thematic equity offerings, including the Climate Solutions and Ocean Engagement strategies. Prior to joining Rockefeller in 2019, Clark was Managing Director and Director of Sustainable and Impact Investing at Glenmede, instrumental in launching and building its business.

“As RAM’s business continues to evolve across fundamental, systematic and thematic investment strategies, Casey is perfectly suited to lead our next phase of growth, which includes expanding our investment platform to provide clients greater access to our differentiated sustainable investing capabilities,” said Gregory Fleming, President & CEO of Rockefeller Capital Management. “Over the last four years, RAM has evolved from a fundamental long-only manager to a leader across multiple disciplines. We look forward to even more innovation ahead under Casey’s leadership, with continuing rigor around our pursuit of alpha and positive outcomes for clients.”

Clark holds an MBA from New York University’s Stern School of Business, a BS in Finance from The Pennsylvania State University and is a Chartered Financial Analyst. He has authored numerous investment and sustainability-related publications and been featured in print and broadcast media segments.

“David Harris has been the leader of our asset management business and an important part of RAM’s success and evolution,” Fleming said. “He will continue to play an important role at the firm over the years to come as we navigate dynamic markets to meet clients' investment objectives.”

Rockefeller has a rich history in sustainable investing, dating back to its first mission-related fund in 1977. In 2021, RAM won the PRI’s prestigious “ESG Incorporation Initiative of the Year,” for its work measuring "ESG Improvers: An Alpha Enhancing Factor". Similarly, in 2019, RAM received the PRI’s “ESG Research Report of the Year Award” for its analysis with the UN assessing the implications of climate change on investment portfolios. RAM was the only U.S.-based asset manager to earn awards both years.

Today, RAM manages $12.8 billion across active equity, fixed income, and alternative strategies.

About Rockefeller Capital Management

Rockefeller Capital Management was established in 2018 as a leading independent, privately-owned financial services firm. Originally founded in 1882 as the family office of John D. Rockefeller, the Firm has evolved to offer strategic advice to ultra-high-net-worth and high-net-worth individuals and families, institutions, and corporations from 32 offices across the United States and, this year, in London. As of December 31, 2021, the Firm was responsible for approximately $95 billion in client assets across its three business segments, the Rockefeller Global Family Office (including Private Wealth Management and Family Office), Rockefeller Asset Management and Rockefeller Strategic Advisory.

About Rockefeller Asset Management (RAM)

Rockefeller Asset Management, a division of Rockefeller Capital Management, offers active equity and fixed income strategies across fundamental, systematic, and thematic approaches that seek outperformance over multiple market cycles, driven by a disciplined investment process and a highly collaborative team culture. With over 30 years of experience in global investing and ESG-integrated research, RAM professionals bring a distinctive worldview to fundamental research combining traditional and non-traditional analysis to generate unique insights and outcomes. As of December 31, 2021, Rockefeller Asset Management had $12.8 billion in assets under management. For more information visit https://rcm.rockco.com/ram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kelly Whalen
kwhalen@prosek.com
857.301.9936

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 01:13:00 EET | Press release

Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release

SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye